Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Wheaton Precious Metals Corp trades at $134.1 (market cap $60.46B). The key difference: Wheaton Precious Metals Corp is far larger — about 70× Amphastar Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WPM | |
|---|---|---|
Market Cap | $863.95M | $60.46B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $165.72 |
52-Week Low | $16.87 | $91.02 |
Enterprise Value | $1.26B | $62.34B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Wheaton Precious Metals (WPM) trades at $134.20, up 7.1% in 24 hours, near its pivot point of $134. The stock shows strong momentum with bullish moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.19 versus $1.15 estimated, driven by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income margins exceeding 64%, while valuation ratios like P/E of 29.77 reflect premium pricing. Analysts maintain an 80% buy rating with a $161.75 consensus target.
Outlook remains positive due to robust cash flow growth and exposure to rising gold/silver prices, but risks include commodity volatility and high valuations. Institutional buying supports upside, though technical indicators suggest near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
